Real-world characteristics of patients with severe asthma prior to starting dupilumab: the ProVENT study
Introduction: Dupilumab is approved for the treatment of severe type 2 (T2) asthma; however, the characteristics of patients receiving dupilumab in routine clinical practice are incompletely understood. This study describes the characteristics of patients with severe asthma before dupilumab treatmen...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2024
|
| In: |
Respiration
Year: 2024, Jahrgang: 103, Heft: 1, Pages: 10-21 |
| ISSN: | 1423-0356 |
| DOI: | 10.1159/000535390 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000535390 Verlag, lizenzpflichtig, Volltext: https://karger.com/res/article/103/1/10/871445/Real-World-Characteristics-of-Patients-with-Severe 
|
| Verfasserangaben: | Stephanie Korn, Olaf Schmidt, Hartmut Timmermann, Henrik Watz, Monika Gappa, Amr Radwan, Lucia De Prado Gomez, Anne Atenhan, Sebastian Barbus, Mayank Thakur, Marek Lommatzsch |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1886457441 | ||
| 003 | DE-627 | ||
| 005 | 20240703170233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240422s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000535390 |2 doi | |
| 035 | |a (DE-627)1886457441 | ||
| 035 | |a (DE-599)KXP1886457441 | ||
| 035 | |a (OCoLC)1443669349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Korn, Stephanie |d 1980- |e VerfasserIn |0 (DE-588)131754483 |0 (DE-627)513603298 |0 (DE-576)298718855 |4 aut | |
| 245 | 1 | 0 | |a Real-world characteristics of patients with severe asthma prior to starting dupilumab |b the ProVENT study |c Stephanie Korn, Olaf Schmidt, Hartmut Timmermann, Henrik Watz, Monika Gappa, Amr Radwan, Lucia De Prado Gomez, Anne Atenhan, Sebastian Barbus, Mayank Thakur, Marek Lommatzsch |
| 264 | 1 | |c January 2024 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.04.2024 | ||
| 500 | |a Online verfügbar: 12 Dezember 2023 | ||
| 520 | |a Introduction: Dupilumab is approved for the treatment of severe type 2 (T2) asthma; however, the characteristics of patients receiving dupilumab in routine clinical practice are incompletely understood. This study describes the characteristics of patients with severe asthma before dupilumab treatment in a real-world setting. Methods: This interim analysis of an ongoing real-life study of dupilumab assessed baseline characteristics of the first patient cohort enrolled in the ProVENT study. Results: A total of 99 patients (59% females) were analyzed (17% received another biologic before dupilumab treatment and 15% were on maintenance oral corticosteroid treatment). Adult-onset asthma (>18 years) and an allergic phenotype were documented in 58% and 48% of patients, respectively. Median (interquartile range) age was 54 (40-61) years; the median number of exacerbations in the last 24 months was 1 (0-3); median fractional exhaled nitric oxide (FeNO) value was 38 (23-64) ppb; and median blood eosinophils (bEOS) count was 184 (8-505) cells/mu L. According to the United Kingdom Severe Asthma Registry classification, 53% of patients had T2 intermediate asthma (bEOS >= 150 cells/mu L or FeNO >= 25 ppb), 17% had T2 high asthma (bEOS >= 150 cells/mu L and FeNO >= 25 ppb), and 4% had T2 low asthma (bEOS <150 cells/mu L and FeNO <25 ppb). At least one GINA criterion for T2 airway inflammation was documented in 70% of patients. T2 comorbidities were observed in 64% of patients. Conclusions: This analysis suggests that patients eligible for dupilumab treatment display various clinical and biochemical characteristics rather than one clear-cut phenotype. | ||
| 650 | 4 | |a Blood eosinophils | |
| 650 | 4 | |a Dupilumab | |
| 650 | 4 | |a Fractional exhaled nitric oxide | |
| 650 | 4 | |a ProVENT | |
| 650 | 4 | |a Type 2 asthma | |
| 700 | 1 | |a Schmidt, Olaf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Timmermann, Hartmut |e VerfasserIn |0 (DE-588)106671438X |0 (DE-627)817835415 |0 (DE-576)426120744 |4 aut | |
| 700 | 1 | |a Watz, Henrik |d 1971- |e VerfasserIn |0 (DE-588)124250815 |0 (DE-627)085737321 |0 (DE-576)294088156 |4 aut | |
| 700 | 1 | |a Gappa, Monika |d 1963- |e VerfasserIn |0 (DE-588)129912492 |0 (DE-627)483081396 |0 (DE-576)297899651 |4 aut | |
| 700 | 1 | |a Radwan, Amr |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Prado Gomez, Lucia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Atenhan, Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bărbuş, Sebastian Liviu |e VerfasserIn |0 (DE-588)1019812281 |0 (DE-627)691026513 |0 (DE-576)358911214 |4 aut | |
| 700 | 1 | |a Thakur, Mayank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lommatzsch, Marek |d 1973- |e VerfasserIn |0 (DE-588)123105129 |0 (DE-627)082350167 |0 (DE-576)293558086 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiration |d Basel : Karger, 1968 |g 103(2024), 1 vom: Jan., Seite 10-21 |h Online-Ressource |w (DE-627)26551035X |w (DE-600)1464419-8 |w (DE-576)112815111 |x 1423-0356 |7 nnas |a Real-world characteristics of patients with severe asthma prior to starting dupilumab the ProVENT study |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:1 |g month:01 |g pages:10-21 |g extent:11 |a Real-world characteristics of patients with severe asthma prior to starting dupilumab the ProVENT study |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000535390 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://karger.com/res/article/103/1/10/871445/Real-World-Characteristics-of-Patients-with-Severe |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240422 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 131754483 |a Korn, Stephanie |m 131754483:Korn, Stephanie |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK131754483 |e 950000PK131754483 |e 950900PK131754483 |e 50000PK131754483 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1886457441 |e 4514284181 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 22.04.2024","Online verfügbar: 12 Dezember 2023"],"recId":"1886457441","relHost":[{"part":{"extent":"11","volume":"103","pages":"10-21","text":"103(2024), 1 vom: Jan., Seite 10-21","year":"2024","issue":"1"},"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Vol. 25, no. 1 (1968)-"],"origin":[{"publisherPlace":"Basel","dateIssuedKey":"1968","publisher":"Karger","dateIssuedDisp":"1968-"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1464419-8"],"eki":["26551035X"],"issn":["1423-0356"]},"recId":"26551035X","note":["Gesehen am 03.07.2024"],"title":[{"title_sort":"Respiration","subtitle":"international journal of thoracic medicine","title":"Respiration"}],"language":["eng"],"disp":"Real-world characteristics of patients with severe asthma prior to starting dupilumab the ProVENT studyRespiration"}],"person":[{"roleDisplay":"VerfasserIn","role":"aut","family":"Korn","display":"Korn, Stephanie","given":"Stephanie"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schmidt, Olaf","family":"Schmidt","given":"Olaf"},{"display":"Timmermann, Hartmut","family":"Timmermann","role":"aut","roleDisplay":"VerfasserIn","given":"Hartmut"},{"given":"Henrik","role":"aut","roleDisplay":"VerfasserIn","display":"Watz, Henrik","family":"Watz"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Gappa, Monika","family":"Gappa","given":"Monika"},{"given":"Amr","family":"Radwan","display":"Radwan, Amr","role":"aut","roleDisplay":"VerfasserIn"},{"given":"Lucia","family":"De Prado Gomez","display":"De Prado Gomez, Lucia","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Atenhan, Anne","family":"Atenhan","role":"aut","roleDisplay":"VerfasserIn","given":"Anne"},{"given":"Sebastian Liviu","family":"Bărbuş","display":"Bărbuş, Sebastian Liviu","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Thakur","display":"Thakur, Mayank","given":"Mayank"},{"given":"Marek","family":"Lommatzsch","display":"Lommatzsch, Marek","roleDisplay":"VerfasserIn","role":"aut"}],"id":{"eki":["1886457441"],"doi":["10.1159/000535390"]},"name":{"displayForm":["Stephanie Korn, Olaf Schmidt, Hartmut Timmermann, Henrik Watz, Monika Gappa, Amr Radwan, Lucia De Prado Gomez, Anne Atenhan, Sebastian Barbus, Mayank Thakur, Marek Lommatzsch"]},"language":["eng"],"title":[{"title_sort":"Real-world characteristics of patients with severe asthma prior to starting dupilumab","subtitle":"the ProVENT study","title":"Real-world characteristics of patients with severe asthma prior to starting dupilumab"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"11 S."}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"January 2024"}]} | ||
| SRT | |a KORNSTEPHAREALWORLDC2024 | ||